Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade. [electronic resource]
Producer: 19980805Description: 7-12 p. digitalISSN:- 0002-9149
- Abciximab
- Aged
- Antibodies, Monoclonal -- therapeutic use
- Anticoagulants -- therapeutic use
- Atherectomy, Coronary -- adverse effects
- Double-Blind Method
- Drug Therapy, Combination
- Female
- Heparin -- therapeutic use
- Humans
- Immunoglobulin Fab Fragments -- therapeutic use
- Male
- Middle Aged
- Myocardial Ischemia -- drug therapy
- Platelet Aggregation Inhibitors -- therapeutic use
- Platelet Glycoprotein GPIIb-IIIa Complex -- metabolism
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.